Mucormycosis outbreak, a serious and often fatal invasive fungal infection, has entered the public consciousness in response to an outbreak in India. Thousands of mucormycosis outbreak  cases reported since the second wave of COVID19 cases in India is drawing worldwide attention to this deadly mucormycosis, which is much more common in India. Even before the COVID19 pandemic, the incidence of mucormycosis in India reached 70 times the global average. Epidemiology of mucormycosis in India.

 One billion people worldwide simultaneously Infections and fungal diseases kill about 1.5 million people every year. Gago S. Oladele R.O. Deny DW. Accuracy of assessing global and international rates of fungal infections.

 The mucormycosis epidemic and outbreak in India has highlighted the severity of fungal infections and the relatively weak scientific status of their prevention, diagnosis and treatment. It’s time to take action against mucormycosis. Why is mucor endemic to India even before Covid? It is unclear what conditions make India more hospitable to him than other Southeast Asian countries, which seem to have much in common in terms of habitat. 

Neither China nor the United States, with equally high rates of diabetes, have had many cases of mucor. In a great tweet, Dr Ashwin Rajenesh explains with photographs that mucosal spores are inhaled but are usually removed from the airways by cilia. A predisposing factor to mucosal infection is that many patients receive azithromycin and doxycycline at an early stage of infection. The reason for the increase in mucor is clearly to combat diabetes, and reducing steroid use will help reduce infections.

According to Covid, the disease has been declared a national pandemic. Thousands of people have died from the disease, and the treatments it adopted have led to an increase in them. Yogita Limaye reports that from a public hospital in Pune, one of the hardest-hit areas, the hospital has taken over the hospital of the Mahatma Gandhi Institute of Health Sciences. A medical school in Sevagram city, Maharashtra state, India. COVID has been sick since May 2020. 

The mucormycosis outbreak was one of the unpleasant surprises of the COVID pandemic in the aftermath of MISC, a severe inflammatory syndrome that appears to mainly affect children, and a complex of “persistent COVID” symptoms. 

Mucormycosis is one of several serious fungal diseases affecting COVID patients, including the deadly yeast Candida Auris and some Aspergillus infections, abbreviated as CAPA. The COVID diagnosis seems to be key. In the years before COVID, researchers in Australia and Europe, as well as India, found mucormycosis was particularly acute in patients with uncontrolled diabetes. “Most of them have sub-optimal blood sugar levels. When these patients test positive for COVID, they are usually prescribed high doses of steroids, usually within the first week. Treatment for COVID is not recommended. And this is not science, it is extremely common. Postpartum cases of COVID have been reported. In some countries, this is so common that doctors are beginning to develop treatment algorithms to mitigate the attack. “People with COVID and a diagnosis of infectious disease and cancer transplant programs,” says Kieren Marr, a physician at Johns Hopkins University School of Medicine and medical director of the Infectious Disease and Cancer Transplant Program high-risk yeast infections in COVID patients.